Resistant CML: Understanding the Science to Change Outcomes

Slides:



Advertisements
Similar presentations
Dr N M Butt Consultant Haematologist
Advertisements

A Proposal for BMS (Dasatinib) in GIST Jon Trent, MD, PhD Assistant Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson.
Imatinib Resistance Geoffrey L. Uy, M.D. Associate Professor of Medicine Division of Oncology.
The National CML Society 2012 CML UPDATE “What’s New? What’s Coming?” Luke Akard MD Co-Director Indiana Blood and Marrow Transplantation Program.
Chronic Myeloid Leukemia: Treatment Success and Milestones
Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.
OHSU Updates in Hematology and Breast Cancer Conference CML ASH Update Michael J. Mauro, MD.
DR Discontinuation of second generation tyrosine kinase inhibitors CML and MPDs UK national meeting Newcastle, March 1 st, 2013 Dr Delphine Rea Service.
Case based discussion Pankaj Malhotra PGIMER, Chandigarh, India.
Stopping TKI treatment in CML: Who and when
1 Rea D et al. Proc ASH 2014;Abstract 811.
Ponatinib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cortes JE et al. Proc ASH 2013;Abstract 1483.
Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Updated Results of the STIM 1 Discontinuation.
What are the risks and benefits of Tyrosine Kinase Inhibitors ? Wendy Osborne Consultant Haematologist Freeman Hospital, Newcastle.
An Ongoing Phase 3 Study of Bosutinib (SKI-606) versus Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Gambacorti-Passerini.
Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Lipton JH.
Dr Nauman Butt – Royal Liverpool University Hospital CML Patient Seminar - 14 th November 2015 What is CML? How do we treat it? Get up to speed…
Initial Findings from the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib,
A Pivotal Phase 2 Trial of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR ‐ ABL Mutation:
Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)
Bosutinib as Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-Up Update Cortes.
Future of CML treatments – Are they getting us closer to cure? Andreas Hochhaus Universitätsklinikum Jena, Germany.
Kantarjian HM et al. Proc ASH 2012;Abstract Long-Term Follow-Up of Ongoing Patients in 2 Studies of Omacetaxine Mepesuccinate for Chronic Myeloid.
Resistance to Targeted Therapy in Chronic Myelogenous Leukemia Andreas Hochhaus, Philipp Erben, Thomas Ernst, and Martin C. Mueller Seminars in Hematology.
Phase III EURO-SKI: Cessation of TKI Therapy Safe, Feasible for Pts Who Achieve Deep Molecular Response New Findings in Hematology: Independent Conference.
HOW TO TREAT FIRST LINE FAILURE?
Shah N et al. Proc ASH 2010;Abstract 206.
Soverini S et al. Proc ASH 2015;Abstract 346.
Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology
Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.
Martinelli G et al. Proc ASH 2015;Abstract 679.
Presented By Luca Malorni at 2017 ASCO Annual Meeting
Nordic sites Sweden Uppsala University Hospital
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC Clinical Focus: Options for Treatment-Resistant or Treatment-Intolerant.
Evolving Paradigms in the Management of HR-Positive Breast Cancer
Ellen K. Ritchie Clinical Director, Richard T. Silver MPN Center
Patient Case 1 Patient Case 1: PET/CT Scan.
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
Clinical Trials in IBD.
The Nurse View Key Insights Along the CML Continuum
Advanced NSCLC Without Actionable Mutations
Cortes JE et al. Proc ASCO 2010;Abstract 6502.
Monitoring Milestones in Patients With Chronic Myeloid Leukemia
Great Debates and Updates in Hematologic Malignancies 2014
Imatinib – where are we now. What about generic imatinib
Optimizing Outcomes in the Management of GIST
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Chronic Myelogenous Leukemia Diagnosis and Treatment
Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams
Advances in Myeloid Malignancies
Novel and Emerging Approaches to Treating CLL
Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?
Mak Shu Ting (18) Yip Pui Yue (29)
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.
Chronic Myeloid Leukemia Challenge
Great Debates-CML Omacetaxine succinate
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Targeting β-catenin in CML: Leukemia Stem Cells Beware!
Evaluating BTK Inhibitors in CLL
Crossover for pts meeting ELN 2013 failure criteria
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
Branford S et al. Proc ASH 2013;Abstract 254.
Third-Generation EGFR TKIs
The Changing Goals of CML Therapy
Targeting Apoptosis in AML
Finding the Right Sequence in Patients With EGFR-Mutated NSCLC
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) for EGFR mutant lung adenocarcinoma.
Chronic Myeloid Leukemia: MD-2025 Chisinau, Republic of Moldova
The Pathway to Progress Against Chronic Myelogenous Leukemia.
Updates in Best Practices in Non-Small Cell Lung Cancer
Presentation transcript:

Resistant CML: Understanding the Science to Change Outcomes

Program Goal

Treating CML With TKIs

Where Do 2nd Generation TKIs Fit in Front-line Therapy?

Late Toxicities

IRIS Trial

Progression-Free Survival: Bosutinib

BELA Trial

Treatment Side Effects

Response Monitoring

European Leukemia Net Guidelines

Frequency of Monitoring Patients

Changing Therapy After Intolerance to Imatinib

TIDEL-II Study

Evaluating Responses

BCR-ABL Mutation Testing

When to Measure Transcript Levels

Evolution of Transcript Level Over Time

Is Resistance Futile?

Ponatinib Pan BCR-ABL Inhibitor

Suppression of Mutant Outgrowth

Phase 1 Study of Ponatinib – Duration of MCyR in CP-CML

PACE Trial

Stop Imatinib (STIM) Study

Thank you for participating in this activity.

Novel Agents for CML

Phase 1 Study: DCC-2036

Phase 1a: Oral Hedgehog Inhibitor PF-04449913

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.